Jim Simons’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.3M | Sell |
8,061,073
-143,900
| -2% | -$590K | 0.04% | 518 |
|
|
2025
Q4 | $27.7M | Sell |
8,204,973
-147,200
| -2% | -$382K | 0.04% | 479 |
|
|
2025
Q3 | $10.9M | Sell |
8,352,173
-53,996
| -0.6% | -$55.9K | 0.01% | 1054 |
|
|
2025
Q2 | $6.03M | Sell |
8,406,169
-1,534,323
| -15% | -$1.2M | 0.01% | 1400 |
|
|
2025
Q1 | $14.6M | Buy |
9,940,492
+874,251
| +10% | +$2.08M | 0.02% | 815 |
|
|
2024
Q4 | $40.2M | Buy |
9,066,241
+469,043
| +5% | +$1.9M | 0.06% | 396 |
|
|
2024
Q3 | $35.4M | Buy |
8,597,198
+25,300
| +0.3% | +$136K | 0.05% | 440 |
|
|
2024
Q2 | $55.9M | Buy |
8,571,898
+1,472,097
| +21% | +$10.4M | 0.09% | 253 |
|
|
2024
Q1 | $61.8M | Buy |
7,099,801
+503,903
| +8% | +$6.11M | 0.1% | 257 |
|
|
2023
Q4 | $75.5M | Buy |
6,595,898
+796,000
| +14% | +$7.87M | 0.12% | 197 |
|
|
2023
Q3 | $55.9M | Buy |
5,799,898
+480,445
| +9% | +$4.71M | 0.1% | 234 |
|
|
2023
Q2 | $56.6M | Buy |
5,319,453
+681,700
| +15% | +$7.33M | 0.08% | 283 |
|
|
2023
Q1 | $48.8M | Buy |
4,637,753
+263,600
| +6% | +$2.95M | 0.06% | 357 |
|
|
2022
Q4 | $54.2M | Sell |
4,374,153
-999,000
| -19% | -$11.3M | 0.07% | 310 |
|
|
2022
Q3 | $55.7M | Sell |
5,373,153
-42,200
| -0.8% | -$478K | 0.08% | 292 |
|
|
2022
Q2 | $62.4M | Buy |
5,415,353
+2,292,300
| +73% | +$27M | 0.07% | 303 |
|
|
2022
Q1 | $39.3M | Buy |
3,123,053
+443,800
| +17% | +$5.09M | 0.05% | 430 |
|
|
2021
Q4 | $31.2M | Buy |
2,679,253
+469,700
| +21% | +$5.76M | 0.04% | 497 |
|
|
2021
Q3 | $28.9M | Sell |
2,209,553
-1,228,500
| -36% | -$15.9M | 0.04% | 502 |
|
|
2021
Q2 | $44.2M | Buy |
3,438,053
+297,300
| +9% | +$3.4M | 0.06% | 374 |
|
|
2021
Q1 | $35.1M | Buy |
3,140,753
+1,135,000
| +57% | +$12M | 0.04% | 492 |
|
|
2020
Q4 | $22.8M | Buy |
2,005,753
+1,088,000
| +119% | +$11.9M | 0.02% | 692 |
|
|
2020
Q3 | $8.26M | Sell |
917,753
-396,100
| -30% | -$3.94M | 0.01% | 1269 |
|
|
2020
Q2 | $13.6M | Sell |
1,313,853
-184,600
| -12% | -$1.89M | 0.01% | 1047 |
|
|
2020
Q1 | $15.1M | Buy |
1,498,453
+744,763
| +99% | +$8.75M | 0.01% | 925 |
|
|
2019
Q4 | $10M | Buy |
753,690
+667,637
| +776% | +$7.36M | 0.01% | 1445 |
|
|
2019
Q3 | $739K | Buy |
+86,053
| New | +$836K | ﹤0.01% | 2713 |
|
|
2019
Q2 | – | Sell |
-426,799
| Closed | -$4.84M | – | 3647 |
|
|
2019
Q1 | $4.84M | Buy |
+426,799
| New | +$4.77M | ﹤0.01% | 1833 |
|
|
2017
Q3 | – | Sell |
-752,522
| Closed | -$11.9M | – | 3271 |
|
|
2017
Q2 | $11.9M | Buy |
752,522
+529,897
| +238% | +$7.7M | 0.02% | 1170 |
|
|
2017
Q1 | $3.18M | Buy |
+222,625
| New | +$3.04M | ﹤0.01% | 1981 |
|
|
2016
Q1 | – | Sell |
-289,608
| Closed | -$2.81M | – | 3440 |
|
|
2015
Q4 | $2.81M | Buy |
289,608
+252,292
| +676% | +$2.44M | 0.01% | 1889 |
|
|
2015
Q3 | $326K | Sell |
37,316
-45,432
| -55% | -$424K | ﹤0.01% | 2741 |
|
|
2015
Q2 | $836K | Buy |
+82,748
| New | +$962K | ﹤0.01% | 2536 |
|
Other funds holding IRWD
AC
SCM
VPM
VCM
Jim Simons's IRWD Position: Q1 2026 in Review
Jim Simons reduced its Ironwood Pharmaceuticals (IRWD) stake by 1.8% in Q1 2026, selling an estimated $590K and leaving 8,061,073 shares worth $28.3M. The position accounts for 0.04% of the portfolio, ranked #518.
Jim Simons first reported a position in IRWD in Q2 2015 and has held it in 33 quarters since. The position peaked at $75.5M in Q4 2023. 227 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.
- Jim Simons held 8,061,073 shares of Ironwood Pharmaceuticals worth $28.3M as of Q1 2026.
- Jim Simons sold 143,900 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $590K.
- Ironwood Pharmaceuticals made up 0.04% of Jim Simons's portfolio in Q1 2026, its #518 holding.
- Jim Simons first reported a position in Ironwood Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
- Jim Simons's Ironwood Pharmaceuticals position peaked at $75.5M in Q4 2023.
- 227 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.